According to a recent LinkedIn post from Osmind, the company is highlighting new research conducted with the American Psychiatric Association on the DSM-5 Cross-Cutting Symptom Measure, published in Frontiers in Psychiatry. The study analyzed real-world data from 3,101 patients across 169 psychiatric practices in 48 states and identified six symptom dimensions plus a general psychopathology factor, suggesting the DSM-XC may be useful for dimensional assessment in outpatient psychiatry.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests this work aligns with the APA DSM Committee’s efforts to use data and precision in shaping the next diagnostic framework. For investors, this type of clinically grounded, large-scale data research could strengthen Osmind’s positioning as a partner in measurement-based care and learning health systems, potentially supporting product differentiation and future adoption among psychiatric practices.
By emphasizing the conversion of routine care data into evidence that informs screening and treatment, the post points to Osmind’s broader strategy around real-world evidence generation. If these capabilities continue to gain traction with key professional bodies and clinicians, the company could see enhanced platform stickiness, better integration into psychiatric workflows, and a stronger long-term competitive moat in mental-health technology.